These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 21144839)

  • 1. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
    Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
    Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
    Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
    BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
    Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
    Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37.
    Prince T; Sun L; Matts RL
    Biochemistry; 2005 Nov; 44(46):15287-95. PubMed ID: 16285732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of chaperoning process by taxifolin: molecular dynamics simulation study.
    Verma S; Singh A; Mishra A
    J Mol Graph Model; 2012 Jul; 37():27-38. PubMed ID: 22609743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and structural studies of the interaction of Cdc37 with Hsp90.
    Zhang W; Hirshberg M; McLaughlin SH; Lazar GA; Grossmann JG; Nielsen PR; Sobott F; Robinson CV; Jackson SE; Laue ED
    J Mol Biol; 2004 Jul; 340(4):891-907. PubMed ID: 15223329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
    J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domain-mediated dimerization of the Hsp90 cochaperones Harc and Cdc37.
    Roiniotis J; Masendycz P; Ho S; Scholz GM
    Biochemistry; 2005 May; 44(17):6662-9. PubMed ID: 15850399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 and Cdc37 -- a chaperone cancer conspiracy.
    Pearl LH
    Curr Opin Genet Dev; 2005 Feb; 15(1):55-61. PubMed ID: 15661534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geldanamycin and its anti-cancer activities.
    Fukuyo Y; Hunt CR; Horikoshi N
    Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
    Ota A; Zhang J; Ping P; Han J; Wang Y
    Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional specificity of co-chaperone interactions with Hsp90 client proteins.
    Riggs DL; Cox MB; Cheung-Flynn J; Prapapanich V; Carrigan PE; Smith DF
    Crit Rev Biochem Mol Biol; 2004; 39(5-6):279-95. PubMed ID: 15763706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 is required for TAK1 stability but not for its activation in the pro-inflammatory signaling pathway.
    Liu XY; Seh CC; Cheung PC
    FEBS Lett; 2008 Dec; 582(29):4023-31. PubMed ID: 19026643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
    J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
    McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
    Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
    Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
    J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inside the Hsp90 inhibitors binding mode through induced fit docking.
    Lauria A; Ippolito M; Almerico AM
    J Mol Graph Model; 2009 Feb; 27(6):712-22. PubMed ID: 19084447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.